Amgen (NASDAQ:AMGN) Earns Neutral Rating from Cantor Fitzgerald

Amgen (NASDAQ:AMGN)‘s stock had its “neutral” rating reiterated by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $350.00 price target on the medical research company’s stock. Cantor Fitzgerald’s target price indicates a potential downside of 1.57% from the company’s current price.

A number of other equities research analysts have also recently commented on the company. TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Wells Fargo & Company increased their price target on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. Morgan Stanley increased their price target on Amgen from $304.00 to $309.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 4th. HSBC reiterated a “buy” rating and issued a $425.00 price target on shares of Amgen in a research note on Wednesday, December 10th. Finally, Mizuho increased their price objective on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $355.16.

Amgen Trading Up 1.7%

Amgen stock opened at $355.60 on Wednesday. The stock has a 50-day moving average of $363.69 and a two-hundred day moving average of $334.30. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen has a one year low of $261.43 and a one year high of $391.29. The stock has a market cap of $191.91 billion, a PE ratio of 24.99, a price-to-earnings-growth ratio of 3.47 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period last year, the business posted $5.31 earnings per share. The firm’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts anticipate that Amgen will post 20.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Anfield Capital Management LLC grew its holdings in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares during the period. Dogwood Wealth Management LLC grew its holdings in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the period. Board of the Pension Protection Fund acquired a new stake in Amgen during the fourth quarter worth about $26,000. Manning & Napier Advisors LLC lifted its holdings in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the period. Finally, Olistico Wealth LLC purchased a new stake in Amgen in the 4th quarter worth approximately $33,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Phase‑3 data for a subcutaneous/on‑body TEPEZZA injector showed strong efficacy and safety vs IV, potentially enabling at‑home dosing and broader use for Thyroid Eye Disease — this could expand TEPEZZA’s addressable market and improve convenience-driven uptake. Amgen’s TEPEZZA Injector Data Sparks Questions On Value And Competition
• Positive Sentiment: Royal Bank of Canada lifted its price target to $370, a bullish signal that supports upside versus prior analyst levels and may underpin buying interest. Royal Bank Of Canada Increases Amgen Price Target to $370
• Positive Sentiment: Investors continue to focus on Amgen’s push into GLP‑1/obesity (MariTide — move to a once‑quarterly injectable was highlighted), which positions the company in a high‑growth segment and complements its existing biologics portfolio. We Picked Amgen Stock a Year Ago. Stick With the Emerging GLP-1 Play.
• Neutral Sentiment: Analysts/market pieces note recent share gains and market outperformance, reflecting broader healthcare strength and momentum rather than company‑specific catalysts alone. Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
• Neutral Sentiment: Guggenheim and Cantor Fitzgerald have maintained/reaffirmed neutral ratings ($351 and $350 targets respectively), signaling limited near‑term upside from their perspectives and keeping sentiment mixed. Guggenheim Adjusts Amgen Price Target Cantor Fitzgerald Reaffirms Neutral
• Negative Sentiment: Morgan Stanley kept a Hold and a $309 target, highlighting limited near‑term upside and providing a counterweight to bullish notes — this could pressure sentiment if investors focus on valuation gaps. Amgen: Long-Term AI Potential but Limited Near-Term Upside Supports Hold Rating
• Negative Sentiment: Competitive pressure from Eli Lilly (and other GLP‑1 leaders) and debates over IMID positioning remain a risk to market share and pricing power in obesity/immunology categories. Eli Lilly Vs. Amgen: Who Leads Obesity And IMIDs

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.